Actively Recruiting
Phase II Study of Ivonescimab Plus CAPOX Chemotherapy for Patients with Unresectable Colorectal Cancer Liver Metastases
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2025-10-01
40
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ivonescimab combined with chemotherapy to treat patients with colorectal cancer that has spread to the liver and cannot be fully removed by surgery. This Phase II clinical trial aims to see if this combination increases the rate of tumor response and to understand the safety and medical issues participants might experience. The study focuses on patients with liver-only metastases that are initially unresectable or borderline resectable. Participants will receive ivonescimab at 20 mgkg on day 1 every 3 weeks along with chemotherapy drugs oxaliplatin and capecitabine following a specific dosing schedule. Treatment is given in cycles of 21 days, up to a maximum of 8 cycles. During the study, participants will visit the clinic every 6 weeks for checkups and tests, and after treatment cycles, they may have surgery, maintenance therapy, or stop study treatment based on expert evaluation. Throughout the trial, participants will undergo regular assessments to monitor tumor response using standardized criteria, document any side effects or adverse events, and evaluate survival outcomes up to two years. Safety monitoring extends up to 180 days after treatment cycles. The total duration of participation depends on treatment response, surgery, and follow-up assessments to gather comprehensive data on the therapys impact.
CONDITIONS
Brief Title
Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases
Research Team
L
Lin Yang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here